Indian pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) and the Russian Direct Investment Fund (RDIF) announced on Tuesday the launch of adaptive phase 2/3 clinical trials for the Sputnik V COVID-19 vaccine in India.
India's Central Drugs Laboratory has approved the multicentre and randomised controlled trial, which will include safety and immunogenicity study.
RDIF recently announced the second interim analysis of clinical trial data, which showed 91.4% efficacy for the vaccine on day 28 after the first dose and efficacy over 95% 42 days after the first dose.
Approximately 40,000 volunteers are currently taking part in Phase III clinical trials of Sputnik V, of whom over 22,000 have been vaccinated with the first dose of the vaccine and more than 19,000 with both the first and second doses.
Dr. Reddy's and RDIF entered into a partnership in September 2020 to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients